These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 7975855)

  • 1. Increased encapsulation and virulence of Francisella tularensis live vaccine strain (LVS) by subculturing on synthetic medium.
    Cherwonogrodzky JW; Knodel MH; Spence MR
    Vaccine; 1994 Jul; 12(9):773-5. PubMed ID: 7975855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain.
    Pechous R; Celli J; Penoske R; Hayes SF; Frank DW; Zahrt TC
    Infect Immun; 2006 Aug; 74(8):4452-61. PubMed ID: 16861631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS.
    Li J; Ryder C; Mandal M; Ahmed F; Azadi P; Snyder DS; Pechous RD; Zahrt T; Inzana TJ
    Microbiology (Reading); 2007 Sep; 153(Pt 9):3141-3153. PubMed ID: 17768257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further Characterization of the Capsule-Like Complex (CLC) Produced by
    Champion AE; Bandara AB; Mohapatra N; Fulton KM; Twine SM; Inzana TJ
    Front Cell Infect Microbiol; 2018; 8():182. PubMed ID: 29963499
    [No Abstract]   [Full Text] [Related]  

  • 5. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.
    Jia Q; Lee BY; Bowen R; Dillon BJ; Som SM; Horwitz MA
    Infect Immun; 2010 Oct; 78(10):4341-55. PubMed ID: 20643859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity.
    Sebastian S; Dillon ST; Lynch JG; Blalock LT; Balon E; Lee KT; Comstock LE; Conlan JW; Rubin EJ; Tzianabos AO; Kasper DL
    Infect Immun; 2007 May; 75(5):2591-602. PubMed ID: 17296751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.
    Jia Q; Bowen R; Lee BY; Dillon BJ; Masleša-Galić S; Horwitz MA
    Vaccine; 2016 Sep; 34(41):4969-4978. PubMed ID: 27577555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response.
    Barrigan LM; Tuladhar S; Brunton JC; Woolard MD; Chen CJ; Saini D; Frothingham R; Sempowski GD; Kawula TH; Frelinger JA
    Infect Immun; 2013 Jun; 81(6):2028-42. PubMed ID: 23529616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
    KuoLee R; Harris G; Conlan JW; Chen W
    Vaccine; 2007 May; 25(19):3781-91. PubMed ID: 17346863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease.
    Green M; Choules G; Rogers D; Titball RW
    Vaccine; 2005 Apr; 23(20):2680-6. PubMed ID: 15780452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
    Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
    Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis.
    Fulop M; Mastroeni P; Green M; Titball RW
    Vaccine; 2001 Aug; 19(31):4465-72. PubMed ID: 11483272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine.
    Twine S; Byström M; Chen W; Forsman M; Golovliov I; Johansson A; Kelly J; Lindgren H; Svensson K; Zingmark C; Conlan W; Sjöstedt A
    Infect Immun; 2005 Dec; 73(12):8345-52. PubMed ID: 16299332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and stabilization of Francisella tularensis live vaccine strain.
    Ohtake S; Martin RA; Saxena A; Lechuga-Ballesteros D; Santiago AE; Barry EM; Truong-Le V
    J Pharm Sci; 2011 Aug; 100(8):3076-3087. PubMed ID: 21491457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.
    Kim TH; Pinkham JT; Heninger SJ; Chalabaev S; Kasper DL
    J Infect Dis; 2012 Apr; 205(7):1056-65. PubMed ID: 21969334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.
    Chen W; Shen H; Webb A; KuoLee R; Conlan JW
    Vaccine; 2003 Sep; 21(25-26):3690-700. PubMed ID: 12922099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Francisella tularensis vaccines.
    Griffin KF; Oyston PC; Titball RW
    FEMS Immunol Med Microbiol; 2007 Apr; 49(3):315-23. PubMed ID: 17316369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.
    Wayne Conlan J; Shen H; Kuolee R; Zhao X; Chen W
    Vaccine; 2005 Mar; 23(19):2477-85. PubMed ID: 15752834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine.
    Drabick JJ; Narayanan RB; Williams JC; Leduc JW; Nacy CA
    Am J Med Sci; 1994 Aug; 308(2):83-7. PubMed ID: 8042659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.
    Wu TH; Hutt JA; Garrison KA; Berliba LS; Zhou Y; Lyons CR
    Infect Immun; 2005 May; 73(5):2644-54. PubMed ID: 15845466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.